Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

NCT02670434 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia
Dyslipidemia

Interventions

DRUG: NK-104-CR
DRUG: Placebo
DRUG: Livalo

Sponsor

Kowa Research Institute, Inc.